Browse PPP2R1A

Summary
SymbolPPP2R1A
Nameprotein phosphatase 2, regulatory subunit A, alpha
Aliases PR65A; PP2A-Aalpha; protein phosphatase 2A, regulatory subunit A, alpha isoform; protein phosphatase 2, 65kD ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Chromosome, centromere Lateral cell membrane Cell projection, dendrite Note=Centromeric localization requires the presence of BUB1.
Domain PF02985 HEAT repeat
Function

The PR65 subunit of protein phosphatase 2A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit. Upon interaction with GNA12 promotes dephosphorylation of microtubule associated protein TAU/MAPT (PubMed:15525651). Required for proper chromosome segregation and for centromeric localization of SGO1 in mitosis (PubMed:16580887).

> Gene Ontology
 
Biological Process GO:0000070 mitotic sister chromatid segregation
GO:0000086 G2/M transition of mitotic cell cycle
GO:0000184 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay
GO:0000188 inactivation of MAPK activity
GO:0000212 meiotic spindle organization
GO:0000226 microtubule cytoskeleton organization
GO:0000819 sister chromatid segregation
GO:0000956 nuclear-transcribed mRNA catabolic process
GO:0001556 oocyte maturation
GO:0001558 regulation of cell growth
GO:0001933 negative regulation of protein phosphorylation
GO:0006260 DNA replication
GO:0006275 regulation of DNA replication
GO:0006401 RNA catabolic process
GO:0006402 mRNA catabolic process
GO:0006469 negative regulation of protein kinase activity
GO:0006470 protein dephosphorylation
GO:0006643 membrane lipid metabolic process
GO:0006665 sphingolipid metabolic process
GO:0006672 ceramide metabolic process
GO:0006997 nucleus organization
GO:0006998 nuclear envelope organization
GO:0007051 spindle organization
GO:0007059 chromosome segregation
GO:0007062 sister chromatid cohesion
GO:0007067 mitotic nuclear division
GO:0007084 mitotic nuclear envelope reassembly
GO:0007126 meiotic nuclear division
GO:0007135 meiosis II
GO:0007143 female meiotic division
GO:0007259 JAK-STAT cascade
GO:0007260 tyrosine phosphorylation of STAT protein
GO:0007281 germ cell development
GO:0007292 female gamete generation
GO:0008380 RNA splicing
GO:0009994 oocyte differentiation
GO:0010921 regulation of phosphatase activity
GO:0016049 cell growth
GO:0016055 Wnt signaling pathway
GO:0016311 dephosphorylation
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019439 aromatic compound catabolic process
GO:0019932 second-messenger-mediated signaling
GO:0021700 developmental maturation
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0030111 regulation of Wnt signaling pathway
GO:0030308 negative regulation of cell growth
GO:0031468 nuclear envelope reassembly
GO:0033673 negative regulation of kinase activity
GO:0034047 regulation of protein phosphatase type 2A activity
GO:0034655 nucleobase-containing compound catabolic process
GO:0035303 regulation of dephosphorylation
GO:0035304 regulation of protein dephosphorylation
GO:0038034 signal transduction in absence of ligand
GO:0042326 negative regulation of phosphorylation
GO:0042503 tyrosine phosphorylation of Stat3 protein
GO:0042509 regulation of tyrosine phosphorylation of STAT protein
GO:0042516 regulation of tyrosine phosphorylation of Stat3 protein
GO:0042518 negative regulation of tyrosine phosphorylation of Stat3 protein
GO:0042532 negative regulation of tyrosine phosphorylation of STAT protein
GO:0043405 regulation of MAP kinase activity
GO:0043407 negative regulation of MAP kinase activity
GO:0043409 negative regulation of MAPK cascade
GO:0043666 regulation of phosphoprotein phosphatase activity
GO:0043900 regulation of multi-organism process
GO:0044270 cellular nitrogen compound catabolic process
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044839 cell cycle G2/M phase transition
GO:0045132 meiotic chromosome segregation
GO:0045144 meiotic sister chromatid segregation
GO:0045926 negative regulation of growth
GO:0046425 regulation of JAK-STAT cascade
GO:0046426 negative regulation of JAK-STAT cascade
GO:0046700 heterocycle catabolic process
GO:0048469 cell maturation
GO:0048477 oogenesis
GO:0048599 oocyte development
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050732 negative regulation of peptidyl-tyrosine phosphorylation
GO:0051052 regulation of DNA metabolic process
GO:0051177 meiotic sister chromatid cohesion
GO:0051231 spindle elongation
GO:0051232 meiotic spindle elongation
GO:0051304 chromosome separation
GO:0051306 mitotic sister chromatid separation
GO:0051321 meiotic cell cycle
GO:0051348 negative regulation of transferase activity
GO:0051445 regulation of meiotic cell cycle
GO:0051754 meiotic sister chromatid cohesion, centromeric
GO:0060281 regulation of oocyte development
GO:0070192 chromosome organization involved in meiotic cell cycle
GO:0070262 peptidyl-serine dephosphorylation
GO:0070601 centromeric sister chromatid cohesion
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071901 negative regulation of protein serine/threonine kinase activity
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand
GO:0097696 STAT cascade
GO:0098813 nuclear chromosome segregation
GO:0198738 cell-cell signaling by wnt
GO:1900193 regulation of oocyte maturation
GO:1901361 organic cyclic compound catabolic process
GO:1902532 negative regulation of intracellular signal transduction
GO:1903046 meiotic cell cycle process
GO:1903429 regulation of cell maturation
GO:1903537 meiotic cell cycle process involved in oocyte maturation
GO:1903538 regulation of meiotic cell cycle process involved in oocyte maturation
GO:1904892 regulation of STAT cascade
GO:1904893 negative regulation of STAT cascade
GO:2000241 regulation of reproductive process
GO:2001233 regulation of apoptotic signaling pathway
GO:2001235 positive regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001238 positive regulation of extrinsic apoptotic signaling pathway
GO:2001239 regulation of extrinsic apoptotic signaling pathway in absence of ligand
GO:2001241 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand
Molecular Function GO:0003823 antigen binding
GO:0004721 phosphoprotein phosphatase activity
GO:0004722 protein serine/threonine phosphatase activity
GO:0008601 protein phosphatase type 2A regulator activity
GO:0016791 phosphatase activity
GO:0019208 phosphatase regulator activity
GO:0019888 protein phosphatase regulator activity
GO:0042578 phosphoric ester hydrolase activity
GO:0046982 protein heterodimerization activity
Cellular Component GO:0000159 protein phosphatase type 2A complex
GO:0000775 chromosome, centromeric region
GO:0008287 protein serine/threonine phosphatase complex
GO:0098687 chromosomal region
GO:1903293 phosphatase complex
> KEGG and Reactome Pathway
 
KEGG hsa03015 mRNA surveillance pathway
hsa04071 Sphingolipid signaling pathway
hsa04114 Oocyte meiosis
hsa04151 PI3K-Akt signaling pathway
hsa04152 AMPK signaling pathway
hsa04261 Adrenergic signaling in cardiomyocytes
hsa04350 TGF-beta signaling pathway
hsa04390 Hippo signaling pathway
hsa04530 Tight junction
hsa04728 Dopaminergic synapse
hsa04730 Long-term depression
Reactome R-HSA-4839748: AMER1 mutants destabilize the destruction complex
R-HSA-5467337: APC truncation mutants have impaired AXIN binding
R-HSA-170984: ARMS-mediated activation
R-HSA-8854518: AURKA Activation by TPX2
R-HSA-5467340: AXIN missense mutants destabilize the destruction complex
R-HSA-4839735: AXIN mutants destabilize the destruction complex, activating WNT signaling
R-HSA-166054: Activated TLR4 signalling
R-HSA-1280218: Adaptive Immune System
R-HSA-5620912: Anchoring of the basal body to the plasma membrane
R-HSA-422475: Axon guidance
R-HSA-196299: Beta-catenin phosphorylation cascade
R-HSA-389513: CTLA4 inhibitory signaling
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-380287: Centrosome maturation
R-HSA-5617833: Cilium Assembly
R-HSA-388841: Costimulation by the CD28 family
R-HSA-69273: Cyclin A/B1 associated events during G2/M transition
R-HSA-69231: Cyclin D associated events in G1
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-180024: DARPP-32 events
R-HSA-195253: Degradation of beta-catenin by the destruction complex
R-HSA-1266738: Developmental Biology
R-HSA-4641262: Disassembly of the destruction complex and recruitment of AXIN to the membrane
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-113510: E2F mediated regulation of DNA replication
R-HSA-198753: ERK/MAPK targets
R-HSA-202670: ERKs are inactivated
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-69236: G1 Phase
R-HSA-69206: G1/S Transition
R-HSA-69275: G2/M Transition
R-HSA-180292: GAB1 signalosome
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-70326: Glucose metabolism
R-HSA-70171: Glycolysis
R-HSA-109582: Hemostasis
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-113501: Inhibition of replication initiation of damaged DNA by RB1/E2F1
R-HSA-2995383: Initiation of Nuclear Envelope Reformation
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-163685: Integration of energy metabolism
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-380259: Loss of Nlp from mitotic centrosomes
R-HSA-380284: Loss of proteins required for interphase microtubule organization from the centrosome
R-HSA-68886: M Phase
R-HSA-450294: MAP kinase activation in TLR cascade
R-HSA-5683057: MAPK family signaling cascades
R-HSA-450282: MAPK targets/ Nuclear events mediated by MAP kinases
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-2465910: MASTL Facilitates Mitotic Progression
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-5339716: Misspliced GSK3beta mutants stabilize beta-catenin
R-HSA-68882: Mitotic Anaphase
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-453274: Mitotic G2-G2/M phases
R-HSA-2555396: Mitotic Metaphase and Anaphase
R-HSA-68877: Mitotic Prometaphase
R-HSA-68875: Mitotic Prophase
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-166058: MyD88
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-5654726: Negative regulation of FGFR1 signaling
R-HSA-5654727: Negative regulation of FGFR2 signaling
R-HSA-5654732: Negative regulation of FGFR3 signaling
R-HSA-5654733: Negative regulation of FGFR4 signaling
R-HSA-5675221: Negative regulation of MAPK pathway
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-975957: Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
R-HSA-927802: Nonsense-Mediated Decay (NMD)
R-HSA-2995410: Nuclear Envelope Reassembly
R-HSA-198725: Nuclear Events (kinase and transcription factor activation)
R-HSA-111885: Opioid Signalling
R-HSA-1852241: Organelle biogenesis and maintenance
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-163767: PP2A-mediated dephosphorylation of key metabolic factors
R-HSA-418346: Platelet homeostasis
R-HSA-432142: Platelet sensitization by LDL
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673000: RAF activation
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-195258: RHO GTPase Effectors
R-HSA-5663220: RHO GTPases Activate Formins
R-HSA-380270: Recruitment of mitotic centrosome proteins and complexes
R-HSA-2565942: Regulation of PLK1 Activity at G2/M Transition
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804757: Regulation of TP53 Degradation
R-HSA-6806003: Regulation of TP53 Expression and Degradation
R-HSA-2500257: Resolution of Sister Chromatid Cohesion
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-5358747: S33 mutants of beta-catenin aren't phosphorylated
R-HSA-5358749: S37 mutants of beta-catenin aren't phosphorylated
R-HSA-5358751: S45 mutants of beta-catenin aren't phosphorylated
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-2467813: Separation of Sister Chromatids
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-190236: Signaling by FGFR
R-HSA-5654736: Signaling by FGFR1
R-HSA-5654738: Signaling by FGFR2
R-HSA-5654741: Signaling by FGFR3
R-HSA-5654743: Signaling by FGFR4
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-194315: Signaling by Rho GTPases
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-4791275: Signaling by WNT in cancer
R-HSA-195721: Signaling by Wnt
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-1295596: Spry regulation of FGF signaling
R-HSA-5358752: T41 mutants of beta-catenin aren't phosphorylated
R-HSA-201681: TCF dependent signaling in response to WNT
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-5467348: Truncations of AMER1 destabilize the destruction complex
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
R-HSA-4839743: phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
R-HSA-4839744: truncated APC mutants destabilize the destruction complex
Summary
SymbolPPP2R1A
Nameprotein phosphatase 2, regulatory subunit A, alpha
Aliases PR65A; PP2A-Aalpha; protein phosphatase 2A, regulatory subunit A, alpha isoform; protein phosphatase 2, 65kD ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PPP2R1A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPPP2R1A
Nameprotein phosphatase 2, regulatory subunit A, alpha
Aliases PR65A; PP2A-Aalpha; protein phosphatase 2A, regulatory subunit A, alpha isoform; protein phosphatase 2, 65kD ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PPP2R1A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX STARS Score: 3.94; FDR: 0.025 Resistant to T cell-mediated killing
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolPPP2R1A
Nameprotein phosphatase 2, regulatory subunit A, alpha
Aliases PR65A; PP2A-Aalpha; protein phosphatase 2A, regulatory subunit A, alpha isoform; protein phosphatase 2, 65kD ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PPP2R1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.160.57
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2080.948
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4330.848
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2570.505
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2030.932
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3270.914
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1280.768
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2270.909
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0680.976
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2850.9
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3380.921
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0250.685
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PPP2R1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382707.4-7.40.169
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPPP2R1A
Nameprotein phosphatase 2, regulatory subunit A, alpha
Aliases PR65A; PP2A-Aalpha; protein phosphatase 2A, regulatory subunit A, alpha isoform; protein phosphatase 2, 65kD ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PPP2R1A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPPP2R1A
Nameprotein phosphatase 2, regulatory subunit A, alpha
Aliases PR65A; PP2A-Aalpha; protein phosphatase 2A, regulatory subunit A, alpha isoform; protein phosphatase 2, 65kD ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PPP2R1A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PPP2R1A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPPP2R1A
Nameprotein phosphatase 2, regulatory subunit A, alpha
Aliases PR65A; PP2A-Aalpha; protein phosphatase 2A, regulatory subunit A, alpha isoform; protein phosphatase 2, 65kD ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PPP2R1A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPPP2R1A
Nameprotein phosphatase 2, regulatory subunit A, alpha
Aliases PR65A; PP2A-Aalpha; protein phosphatase 2A, regulatory subunit A, alpha isoform; protein phosphatase 2, 65kD ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PPP2R1A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPPP2R1A
Nameprotein phosphatase 2, regulatory subunit A, alpha
Aliases PR65A; PP2A-Aalpha; protein phosphatase 2A, regulatory subunit A, alpha isoform; protein phosphatase 2, 65kD ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PPP2R1A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPPP2R1A
Nameprotein phosphatase 2, regulatory subunit A, alpha
Aliases PR65A; PP2A-Aalpha; protein phosphatase 2A, regulatory subunit A, alpha isoform; protein phosphatase 2, 65kD ......
Chromosomal Location19q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PPP2R1A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PPP2R1A.
ID Name Drug Type Targets #Targets
DB025062,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic AcidSmall MoleculePPP1CA, PPP2CA, PPP2R1A, PPP2R2A, PPP2R5C5
DB06905(2S,3S,4E,6E,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acidSmall MoleculePPP2CA, PPP2R1A, PPP2R5C3